OPPapers.com Essay Index >> Business >> Biopure Case
We have many free term papers and essays on Biopure Case. We also have a wide variety of research papers and book reports available to you for free. You can browse our collection of term papers or use our search engine.
BioPure case BioPure Corporation, which was founded in 1984 by entrepreneurs Carl Rausch and David Judelson, is a privately owned biopharmaceutical firm specializing
Biopure Case Analysis: Biopure Corporation. Background Analysis: General Market Assessment: Biopure Corporation makes Blood substitutes for animals and human beings.
SearchBrowseCustom EssaysJoinDonateAbout UsSite StatsLogin Links Help Free Term Papers on Biopure Case OPPapers.com Essay Index > Business > Biopure Case We have
to sell Oxyglobin through the distributors as Optimal Gross profit = (you can calculate it) Case 2: Biopure uses its own sales-force: It's given in the case that
it be approved. In this case, it is important to note that the human market already has two competitors who are planning to price between $600 and $800, therefore,
Submitted by cwbegay on April 4, 2005
Category: Business
Words: 1626 | Pages: 7
Views: 1463
Popularity Rank: 3,560
Average Member Grade: N/A (Add a Comment / Grade this Paper)
BioPure Corporation, which was founded in 1984 by entrepreneurs Carl Rausch and David Judelson, is a privately owned biopharmaceutical firm specializing in the ultra purification of proteins for human and veterinary use. In 1998 Biopure pioneered the development of oxygen therapeutics using "Hemoglobin", a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new Oxygen based treatment approach for managing patients' oxygen requirements in a broad range of potential medical applications. The factor distinguishing Biopure's two products from other blood substitute products being developed by two possible rivals, Baxter International and Northfeild Laboratories, is that its hemoglobin based source is bovine rather than human and was derived from the blood cells of cattle. Both of Biopure's blood substitute products were in the final stages of the approval process of the Food and Drug Administration (FDA) in 1998. Oxyglobin had just received the FDA's approval for commercial release declaring it safe and effective for medical use. Hemopure was entering final Phase 3 clinical trials and was optimistically expected to see final FDA approval for release in 1999. The FDA approval of Oxyglobin and its possible subsequent release into the veterinary market caused concern over whether the early release of Hemoglobin would impinge BioPure's ability to price Hemopure when the product finally received approval. Given that the two products were almost identical in properties and function, it was thought that the early release of Oxyglobin would create an unrealistic price expectation for Hemopure if released first.
Although blood transfusions in the veterinary market are infrequent and the market scope is limited, Oxyglobin has the potential to become a lucrative investment for Biopure. Based on the approximate...
You must Login to view the entire paper.
If you are not a member yet, Sign Up for free!